N/A N=9 Behavioral Economics and Communication
Problem Behavior
Primary: Averge of Aappropriate Communication Responses — 3.33 direct observation of 5-min sessions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=30 Behavior Brain Responses
Alcohol Drinking · Drinking Behavior · Physiological Effects of Drugs
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Across Sessions…
N/A N=49 Behavior During Experimentally Induced Pain
Schizophrenia · Major Depression
Primary: Indicators / Minute — 1.925; 0.23; 0.4; 0.45 indicators/minute — p=0.992
N/A N=30 Identifying Precursors to Severe Problem Behavior
Problem Behavior · Aggression
Primary: Severe Problem Behavior (SPB)
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
N/A N=16 Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
Persistent Depressive Disorder
Primary: Paid Work Hours at Week 12 — 30.3 hours — p=0.005
Phase 2 N=16 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Frontotemporal Dementia (FTD)
Primary: Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI) — 7.14; 5.75 score on a scale
Phase 2 N=13 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz Syndrome
Primary: Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C). — 8.6; 8.6 units on a scale — p=1.0
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 2 N=13 Nuedexta for the Treatment of Adults With Autism
Autism
Primary: Change in Maladaptive Behaviors — -6.62; -1.08 units on a scale
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
N/A N=5 Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients
Parkinson's Disease
Primary: Association Between Basal Ganglia Beta Power and Effort Level (Beta Coefficient) — -0.175 beta coefficient — p=0.007
N/A N=30 Environmental Design for Behavioral Regulation in People With Dementia
Alzheimer Disease
Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12
N/A N=32 Elderly Demented Patients: Aromatherapy Complementary to Psychopharmacotherapy Psychological Disorders and BPSD Behavior
BPSD (Behavioral and Psycological Symptoms of Dementia)
Primary: Role of Essential Oil Therapy in Environmental Diffusion as a Complement of Psychotropic Drugs in the Management of Psychological and Behavioral Disorders (BPSD)…
Phase 1 N=19 Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
N/A N=10 Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder
Alcohol Use Disorder · Posttraumatic Stress Disorder
Primary: Timeline Follow-Back (Alcohol Use) — 4.36; 3.90; 1.82; 3.31 Drinks per day — p=0.4174
Phase 2 N=184 Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
Cigarette Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants
N/A N=28 Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits
Anxiety · Depression
Primary: Reaction Time to Facial Affect Identification During Emotional Conflict — 802.15; 889.14; 848.79; 937.97 milliseconds — p=0.004
N/A N=13 Tx for Child Sexual Behavior Problems
Sexual Behavior
Primary: Child Sexual Behavior on the Child Sexual Behavior Inventory (CSBI) — 28.8; 18.1 Scores on a scale
N/A N=3 Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)
Alzheimer Disease
Primary: Acceptability of the tDCS Treatment as Assessed by the tDCS Acceptability Questionnaire
N/A N=16 Enhancement of Behavioral and Cognitive Outcomes in Autism Spectrum Disorder Via Neurostimulation
Autism Spectrum Disorder
Primary: The Effects of rTMS on Reciprocal Social Awareness — 68; 79.667; 64.2; 74 total raw score (higher=worse)
N/A N=24 Correlates of GERD Symptom Severity
GERD
Primary: Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later — -0.94; -1.70 micro-Siemens — p=0.034
Phase 2 N=156 Virtual Patient Behavioral Response Training for Family Caregivers
Alzheimer Disease
Primary: Revised Memory and Behavior Problems Checklist — 0.66; 0.89 units on a scale
N/A N=42 Acceptability and Feasibility of Cognitive Behavioral Therapy for Treatment-Seeking (CBT-TS) With Deaf Individuals
Mental Health Issue · Alcohol Use Disorder · Depression
Primary: Proportion of Participants Who Schedule Professional Treatment — 8 Participants
N/A N=81 Behavioral Activation for PTSD/Depression Treatment in OIF/OEF Veterans
Posttraumatic Stress Disorder · Depression
Primary: Clinician Administered PTSD Scale (CAPS-IV) — 75.9; 82.0; 54.4; 70.1 units on a scale
N/A N=78 Nicotine and Behavior in Adult ADHD
ADHD
Primary: ADHD Symptoms — 71.2; 78.4; 47.4; 55.5 Percent of item endorsement — p=<0.025
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
N/A N=58 Symptom Perception
Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.2; 1.4; 0.8; 1.4 score on a scale
N/A N=664 Behavioral Economics Applications to Geriatrics Leveraging EHRs
Prostate Specific Antigen · Asymptomatic Bacteriuria · Type 2 Diabetes Mellitus
Primary: Misuse of Urinalysis or Urine Culture in Older Women — 25 Participants
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17